Lucas Pitts MD FCCP DAABIP
Critical Care Medicine, Interventional Pulmonology
Assistant Professor, Internal Medicine, University Kansas School of Medicine
Join to View Full Profile
4000 Cambridge, Mailstop 3007Kansas City, KS 66160
Phone+1 913-588-6046
Fax+1 913-588-4098
Dr. Pitts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lucas Pitts is an interventional pulmonologist in Kansas City, KS and is affiliated with The University of Kansas Hospital. He received his medical degree from University of Kansas School of Medicine and has been in practice 12 years. He specializes in advanced diagnostic, robotic, and therapeutic bronchoscopy.
Education & Training
University of Kansas School of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011- University of Kansas School of MedicineResidency, Internal Medicine, 2005 - 2008
- University of Kansas School of MedicineClass of 2005
Certifications & Licensure
MO State Medical License 2021 - 2026
KS State Medical License 2008 - 2025
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
Publications & Presentations
PubMed
- Tracheal stenting by rigid bronchoscopy in right lateral decubitus position in an awake patient.Clarissa B Smith, Lucas Pitts, Maykol Postigo
Heliyon. 2023-08-01 - A rare case of combined small cell lung carcinoma with heterologous component of rhabdomyosarcoma diagnosed by endobronchial ultrasound (EBUS)-guided biopsy.Diego Cedano, Jorge Cedano, Daffolyn Rachael Fels Elliott, Jasmeet Assi, Rashna Madan
Respiratory Medicine Case Reports. 2023-01-01 - 7 citationsSafety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.Kyle R. Brownback, Lucas R. Pitts, Sunil Abhyankar
Bone Marrow Transplantation. 2018-04-26
Professional Memberships
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
